- Charles River and Wheeler Bio have finalised an agreement aimed at accelerating the process from discovery and CMC development to manufacturing.
Charles River and Wheeler Bio have announced the completion of an agreement that promises to accelerate the journey from discovery and CMC development to manufacturing.
This collaboration aims to streamline the process, reducing the time and resources required to transition from the discovery phase to manufacturing.
Charles River, known for its top-notch services in antibody discovery, safety, and analytics, is joining forces with Wheeler’s Portable CMC® platform. This partnership aims to speed up the process from therapeutic discovery to IND submission timelines. This combined service simplifies the journey from preclinical trials to clinical manufacturing and release testing. It also makes managing relationships with multiple vendors less complicated. By bringing CMC development into the early stages of discovery, therapeutic developers can work together with experts across both organisations. This collaboration allows for the use of manufacturing and analytics that are suitable for each phase of development.
“We are thrilled to provide Charles River clients with access to Wheeler’s innovative Portable CMC® platform, which will optimise their workflows and ultimately bring new treatments to patients faster.” –Julie Frearson, Corporate Senior Vice President, Chief Scientific Officer, Charles River.
“Wheeler is excited to expand our relationship with Charles River and to link with their discovery organisation. By integrating discovery CRO and CDMO workflows, we can speed our clients’ path to first-in-human trials, thereby achieving clinical decisions faster. Our combined sales teams look forward to co-promoting these services for the benefit of our biotech partners and their pipelines towards clinical impact.” —Jesse McCool, CEO and Co-Founder, Wheeler Bio.
Overview of outsourcing trends 
